Market Overview

GSK and Theravance Announce Positive Results From Four Pivotal Phase III Studies for Once-Daily LAMA/LABA (UMEC/VI) in COPD

GlaxoSmithKline plc (NYSE: GSK) and Theravance, Inc. (Nasdaq: THRX) today announced the results of four pivotal phase III studies of investigational LAMA/LABA involving over 4,000 patients with chronic obstructive pulmonary disease (COPD).

These four studies include two 24-week efficacy studies that compared the combination LAMA/LABA, its components and placebo and two 24-week active comparator studies that compared the combination with the LAMA tiotropium, a widely prescribed maintenance bronchodilator for COPD.

Posted-In: News FDA

 

Related Articles (THRX + GSK)

Around the Web, We're Loving...

Partner Network

Get Benzinga's Newsletters